Health3 years ago
FDA: This Treatment Probably Won’t Be Effective Against Omicron Subvariant
GlaxoSmithKline’s COVID-19 antibody-drug is unlikely to be effective against the notorious Omicron subvariant known as BA.2, the pharmaceutical giant announced Friday. The company said that regulators...
Recent Comments